Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2025-08-22 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled '2025 年半年度报告摘要' which translates to '2025 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, cash flow, earnings per share, and asset information for the half-year period. It also includes shareholder information and changes in controlling shareholders. The document length is 3107 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. The presence of detailed financial metrics and shareholder data confirms it is a financial report for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). H1 2025
2025-08-22 Chinese
2025年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "海思科医药集团股份有限公司2025 年半年度财务报告" which translates to "Haisco Pharmaceutical Group Co., Ltd. 2025 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2025. The report explicitly states it is a half-year (semi-annual) financial report and includes comprehensive financial data and analysis, not just an announcement or summary. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-22 Chinese
半年报董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 海思科医药集团股份有限公司. It includes voting results on the approval of the 2025 semi-annual report and a funding-related proposal. The document references that the full semi-annual report and related announcements are published elsewhere (on 巨潮资讯网 and other media). The document itself is short (798 characters) and serves as a notice of board decisions rather than containing the full financial report or detailed financial data. This fits the category of Board/Management Information (MANG), as it announces board meeting resolutions and management decisions. It is not the full interim report (IR), nor an announcement of voting results at a shareholder meeting (DVA).
2025-08-22 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 99% confidence The document is titled as the "2025 年半年度报告全文" which translates to the "2025 Semi-Annual Report Full Text" of 海思科医药集团股份有限公司 (Haisco Pharmaceutical Group Co., Ltd.). It contains detailed financial data, management discussion and analysis, business overview, product descriptions, R&D progress, sales and production information, and future plans. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content includes actual financial figures, operational data, and management commentary for the half-year period ending 2025, which fits the definition of an Interim / Quarterly Report (IR). It is not an announcement of a report publication, nor a certification or a regulatory filing. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2025
2025-08-22 Chinese
关于获得创新药HSK39297片新适应症IND申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving an acceptance notice from the National Medical Products Administration for a new drug's clinical trial application. It details the drug, its indications, and regulatory acceptance. The document is short (1394 characters) and serves as an official announcement of regulatory approval to proceed with clinical trials, not a financial report or detailed regulatory filing. It does not contain financial data, management changes, or voting results. It is an announcement of a regulatory event related to drug development. Given the nature and length, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-08-17 Chinese
北京市中伦律师事务所关于海思科医药集团股份有限公司2025年度向特定对象发行A股股票的补充法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a company's planned issuance of A shares to specific investors in 2025. It includes extensive financial data, descriptions of the company's business, product pipelines, R&D projects, administrative penalties, and compliance with regulatory requirements. The document discusses the company's fundraising plans, use of proceeds, and legal compliance related to the issuance. It is not a full annual or quarterly report, nor an earnings release or audit report. It is not a transcript, nor a board or management change announcement. The document is a legal opinion related to a capital raising event (a specific share issuance). Therefore, it fits best under the category of Capital/Financing Update (CAP), as it provides detailed legal and financial information about the company's planned capital raising through a specific share issuance to targeted investors.
2025-08-13 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.